RESEARCH
Area 1
AETIOPATHOGENIC, CELLULAR AND MOLECULAR MECHANISMS IN INFLAMMATORY AND AUTOIMMUNE DISEASES.
Area 1 is made up of 10 lines and 21 research groups, the main aims of which are: deciphering the cellular and molecular mechanisms that control crucial biological processes in autoimmune and inflammatory diseases; identifying molecular entities and cellular processes that may serve as targets for the action of new drugs for inflammatory/autoimmune-based diseases; implementing advanced experimental techniques and new animal models of diseases allowing improvements to basic studies to analyse their pathophysiological mechanisms, and to conduct pre-clinical studies and promote translational research by promoting interaction between basic and clinical groups.
Coordinator
Dr Francisco Sánchez Madrid
Area 2
TRANSLATIONAL NEUROSCIENCE.
Area 2 is made up of 5 research lines, with one group per line. Its general objectives are: the design, synthesis and characterisation of new compounds with potential neuroprotection effects in neurodegenerative disease and cerebrovascular accidents; the search for biomarkers for early diagnosis, the study of disease progression and treatment response; the characterisation of drugs in preclinical trials in animal models and in human clinical trials; and the expansion of knowledge of affective disorders in the population, studying risk factors, clinical evolution and treatment response, with the aim of improving the population’s mental health.
Coordinator
Dr José Luis Ayuso Mateos
Area 3
ADVANCED THERAPY AND PERSONALISED MEDICINE.
Area 3 is made up of 8 research lines and 18 research groups. Among their general objectives are: the identification of biomarkers that allow prognosis and/or treatment response to be predicted when treating inflammatory, infectious or tumour-based diseases; optimisation of biological treatments through identification of biomarkers that predict treatment response; the identification of new drugs and/or treatment targets; and the search for new treatment and improvements in treatment efficacy and safety and management of treatment effects on patient quality of life.
Coordinator
Dr Isidoro González Álvaro
